The FDA has not evaluated compounded versions for safety, quality, or efficacy to the same standard as brand-name medications
Ileus and intestinal blockage: Obstruction in the intestines that can cause severe pain and require surgical intervention
Australia GLP-1 Receptor Agonist Market Size Analysis Market Size (USD Million): 2024: $499.12M 2025: $570.49M 2026: $652.07M 2027: $745.32M 2028: $851.90M 2029: $973.72M 2030: $1,112.97M 2031: $1,272.12M 2032: $1,454.03M 2033: $1,661.96M 2034: $1,899.62M CAGR: 14.30% 2025-34 Australia GLP-1 Receptor Agonist Market Key Drivers and Challenges: Key Market Drivers: Rising Demand for Effective Metabolic Therapies: The growing rates of type 2 diabetes and obesity in Australia are creating a surge in demand for GLP-1 receptor agonists
Whilst the FDA approved the use of oral semaglutide for the treatment of people with T2D in September 2019 [37], the EMA have not approved its use in T2D at the time of writing
However, GLP-1s also offer well-established research with fewer gastrointestinal side effects
Semin Ophthalmol